Gastric Balloon Labeling Updated After Patient Deaths
Executive Summary
US FDA has approved updated labeling for Orbera Intragastric Balloon System and the ReShape Integrated Dual Balloon System in the wake of five more patient deaths.
You may also be interested in...
FDA Updates On Hyperinflation, Pancreatitis Risks Of Implantable Liquid-Filled Weight-Loss Balloons
A letter from the US agency clarifies the risks of over-inflation, acute pancreatitis and death in patients who have been treated with liquid-filled intragastric balloons.
Apollo And ReShape Swap Bariatric Devices
Apollo Endosurgery sold its surgical product line, including the Lap-Band adjustable gastric banding system and other accessories for laparoscopic bariatric surgery, to ReShape Lifesciences for $17m plus other considerations, including the ReShape endoscopic balloon, the companies announced Dec. 18. The deal will allow Apollo to focus on endo-bariatric procedures while it gives ReShape an instant revenue stream and another product to sell to surgeons, its core customers.
Gastric Balloon-Makers Respond To US FDA Warning
Apollo Endosurgery and Reshape Medical are both defending their products’ safety in the wake of a US FDA letter warning of five deaths tied to the companies' intragastric balloon devices.